Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta Group PLC (AIM:AVCT) Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a
Avacta Group PLC (AVCT.L) Expanded Partnership with Daewoong Pharmaceutical
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutrali s ing Affimer Therapy
